IDENTIFICATION OF NOVEL DRUGS FOR INHIBITION OF NUCLEAR FACTOR Κ-B PROTEIN TO TREAT INFLAMMATION-BASED OBESITY USING COMPUTATIONAL TECHNIQUES

Abstract

Inflammation brought on by obesity is linked to several clinically significant consequences, such as insulin resistance, Type 2 diabetes, hypertension, and non-alcoholic fatty liver disease . Adipose tissue plays a crucial role in this process, even though the reason and the participating molecules are still not fully understood . Coordinating controllers of immune and inflammatory reactions, nuclear factor kappa B (NF-κB) transcription factors are genetically conserved . They are crucial in progression of cancer and other metabolic diseases . The IKK/NF-κB signalling has been shown in numerous studies to play a critical role in the induction and maintenance of the inflammatory state that underpins metabolic disorders like type 2 diabetes and obesity . Recently, a crucial function for immune cells, in producing the inflammation, brought on by fat, has been discovered . It may be possible to find treatment targets, that can reduce the problems related to obesity by specifying the cellular and molecular entities of obesity caused by inflammation . In this paper, we have focused on molecular mechanisms and pathways related to obesity based diabetes type-2 and worked on a list of multiple drugs which are commonly approved for different diseases like cancer and hypertension, etc . that can be repurposed to cure diabetes type-2 led by inflammation-based obesity . Out of 250 drugs, Telmisartan, an anti hypertension drug, and Dolutegravir, which is an anti-viral drug resulted as the best binding drug to inhibit NF κ-B and stop the onset of disease .